NCT05280275 - A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 13, 2022

Primary Completion Date

March 15, 2026

Study Completion Date

March 15, 2026

Conditions

Multiple MyelomaNeoplasmsNeoplasms, Plasma CellGammopathy, MonoclonalParaproteinemiasBlood Protein DisordersHaematologic DiseaseCorneal Disease

Interventions

DRUG

Belantamab Mafodotin-Blmf

"Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder.~Blmf will be delivered as IV solution over at least 30 minutes."

DRUG

Daratumumab

Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.

DRUG

Lenalidomide

Lenalidomide will be administered per os.

DRUG

Dexamethasone

Dexamethasone will be administered intravenously or per os.

Trial Locations (2)

11528

RECRUITING

Department of Clinical Therapeutics, School of Medicine, National Kapodistrian University of Athens (NKUA), Athens

54639

RECRUITING

"Anticancer Hospital of Thessaloniki Theageneio", Thessaloniki